BC Extra | Oct 23, 2019
Company News

Oct. 22 Company Quick Takes: Zealand acquires Encycle; plus Novartis, Vitalis, Roche-Spark

Zealand expands peptide platform with Encycle acquisition  Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said it will expand its peptide therapeutics platform through the acquisition of Encycle Therapeutics Inc. In return for all its outstanding shares, access...
BC Week In Review | Oct 5, 2015
Financial News

Encycle Therapeutics completes venture financing

Encycle Therapeutics Inc. , Toronto, Ontario   Business: Chemistry, Autoimmune, Cancer   Date completed: 2015-09-30   Type: Venture financing   Raised: C$2.9 million ($2.1 million)   Investors: Takeda Ventures Inc.; Accel-Rx Health Sciences Accelerator; BDC Capital;...
BC Extra | May 2, 2015
Company News

Merck, PeptiDream to develop macrocycles

Merck & Co. Inc. (NYSE:MRK) and PeptiDream Inc. (Tokyo:4587) have partnered to use the biotech's Peptide Discovery Platform System (PDPS) to generate macrocycles against multiple undisclosed targets selected by Merck. Merck will have the right...
BC Innovations | Dec 18, 2014
Translation in Brief

YABAO GOES BOLD

Yabao goes bold China-based Yabao Pharmaceutical Group Co. Ltd. and MRC Technology are jointly going where Western pharmas and academics fear to tread with a preclinical partnership to develop compounds against an undisclosed kinase target...
BC Innovations | Dec 4, 2014
Strategy

Merck Encycles through Canada

The first disclosed grant under Merck & Co. Inc. 's Canadian translational initiative will bolster the ability of macrocycle-based Encycle Therapeutics Inc. to conduct lead optimization of its integrin α4b7 inhibitors for inflammatory bowel disease....
BioCentury | Aug 4, 2014
Emerging Company Profile

Encycle: Oral macrocycles

Macrocycle therapies can block protein-protein interactions that are undruggable with small molecules; however, oral availability and cell penetration remain key challenges. Encycle Therapeutics Inc. 's chemistry platform generates drug-like macrocycles against validated targets to treat...
BioCentury | Sep 17, 2012
Product Development

Excited about cycling

New synthesis and screening technologies and the allure of access to previously undruggable targets are driving an explosion of new company formation and deal-making around macrocycles and constrained peptides. While it remains to be seen...
BC Week In Review | Jul 9, 2012
Company News

MaRS Innovation, Quebec Consortium for Drug Discovery (CQDM) chemistry news

MaRS Innovation spun out Encycle Therapeutics Inc. to develop a chemistry technology that cyclizes linear peptides for use in drug discovery research. MaRS said that the technology will increase efficiency of the early-stage discovery process...
Items per page:
1 - 8 of 8
BC Extra | Oct 23, 2019
Company News

Oct. 22 Company Quick Takes: Zealand acquires Encycle; plus Novartis, Vitalis, Roche-Spark

Zealand expands peptide platform with Encycle acquisition  Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said it will expand its peptide therapeutics platform through the acquisition of Encycle Therapeutics Inc. In return for all its outstanding shares, access...
BC Week In Review | Oct 5, 2015
Financial News

Encycle Therapeutics completes venture financing

Encycle Therapeutics Inc. , Toronto, Ontario   Business: Chemistry, Autoimmune, Cancer   Date completed: 2015-09-30   Type: Venture financing   Raised: C$2.9 million ($2.1 million)   Investors: Takeda Ventures Inc.; Accel-Rx Health Sciences Accelerator; BDC Capital;...
BC Extra | May 2, 2015
Company News

Merck, PeptiDream to develop macrocycles

Merck & Co. Inc. (NYSE:MRK) and PeptiDream Inc. (Tokyo:4587) have partnered to use the biotech's Peptide Discovery Platform System (PDPS) to generate macrocycles against multiple undisclosed targets selected by Merck. Merck will have the right...
BC Innovations | Dec 18, 2014
Translation in Brief

YABAO GOES BOLD

Yabao goes bold China-based Yabao Pharmaceutical Group Co. Ltd. and MRC Technology are jointly going where Western pharmas and academics fear to tread with a preclinical partnership to develop compounds against an undisclosed kinase target...
BC Innovations | Dec 4, 2014
Strategy

Merck Encycles through Canada

The first disclosed grant under Merck & Co. Inc. 's Canadian translational initiative will bolster the ability of macrocycle-based Encycle Therapeutics Inc. to conduct lead optimization of its integrin α4b7 inhibitors for inflammatory bowel disease....
BioCentury | Aug 4, 2014
Emerging Company Profile

Encycle: Oral macrocycles

Macrocycle therapies can block protein-protein interactions that are undruggable with small molecules; however, oral availability and cell penetration remain key challenges. Encycle Therapeutics Inc. 's chemistry platform generates drug-like macrocycles against validated targets to treat...
BioCentury | Sep 17, 2012
Product Development

Excited about cycling

New synthesis and screening technologies and the allure of access to previously undruggable targets are driving an explosion of new company formation and deal-making around macrocycles and constrained peptides. While it remains to be seen...
BC Week In Review | Jul 9, 2012
Company News

MaRS Innovation, Quebec Consortium for Drug Discovery (CQDM) chemistry news

MaRS Innovation spun out Encycle Therapeutics Inc. to develop a chemistry technology that cyclizes linear peptides for use in drug discovery research. MaRS said that the technology will increase efficiency of the early-stage discovery process...
Items per page:
1 - 8 of 8